Jiangsu Recbio Technology Co. Ltd, a leading biopharmaceutical company from China, has signed a licensing and technology transfer agreement with Hyderabad-based Biological E Limited (BE) for its Recombinant 9-valent HPV vaccine, REC603. The vaccine is designed to protect against nine strains of Human Papillomavirus (HPV), including those that cause cervical, vulvar, vaginal, anal, oropharyngeal cancers, and genital warts.
🧬 What the Deal Involves
Under the agreement:
- BE will have exclusive rights to commercialise REC603 in India.
- BE can also participate in global tenders issued by UNICEF and PAHO (Pan American Health Organization).
- Recbio will supply the Drug Substance (DS) and transfer formulation, filling, and packaging technologies to BE.
- Technology for DS production will also be shared at a later stage.
- Recbio has already started transferring technical expertise and materials, and will support BE through clinical development and regulatory approvals in India.
🏭 Manufacturing and Global Goals
The local production of REC603 by BE is aimed at meeting the rising global demand for cervical cancer prevention. According to the companies, large-scale manufacturing will begin once the technology transfer is fully complete.
🗣️ Company Statements
Dr Liu Yong, Chairman and CEO of Recbio, hailed the partnership as a “major milestone in the global expansion” of their vaccine pipeline.
Mahima Datla, Managing Director of Biological E, said the deal reflects their ongoing commitment to making life-saving vaccines more affordable and accessible, especially in low- and middle-income countries.
This collaboration is expected to significantly boost India’s HPV immunisation efforts, while also expanding the global availability of affordable vaccines in the fight against HPV-related cancers.
